Greenland Mines (NASDAQ: GRML) announced on July 28, 2026, that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The Canadian patent expands Greenland Mines’ intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This broadens the company's protection in key markets, which is critical for a biotech firm developing novel gene therapies. The company also provided updates on its lead candidates: process development and manufacturing for KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. These milestones indicate progress toward clinical trials.
This news is significant because it underscores the company’s dual focus on mining and biotech, as described in its corporate structure. Greenland Mines operates two divisions: Mining, focused on the Skaergaard Project and the Sarfartoq rare earths project in Greenland; and Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
For investors and the medical community, the granting of a Canadian patent strengthens Greenland Mines’ position in the competitive gene therapy landscape. The 42 claims cover synthesis, delivery methods, and applications across multiple neurological disorders, potentially offering a broad therapeutic platform. The advancement of KLTO-202 to GMP manufacturing is a key step toward clinical trials, which could lead to new treatments for ALS, a devastating disease with limited options. Similarly, KLTO-101’s progress suggests a pipeline that may address Alzheimer’s and other conditions.
However, forward-looking statements caution that actual results may differ materially due to risks and uncertainties, including those in the company’s SEC filings. The full press release is available at https://ibn.fm/x2pHAA, and updates can be found in the company’s newsroom at https://ibn.fm/GRML.
